Blog

The use of non-verbal communication with the intent to harm a partner mentally or emotionally or to exert control over a partner is known as….

Condylomata lata is associated with which of the following conditions.

You are seeing a patient for a new OB visit and you note that her pre-pregnancy BMI is 28.2. Which of the following represents the recommended weight gain for this singleton pregnancy? 

The standard cell potential is 1.31 V for the reaction 2Fe3+ + 2I−(aq) → 2Fe2+(aq) + ​I2​(s) . Determine the equilibrium constant value for this cell. 

A 48-year-old obese male presents to the clinic with a 1-year history of GERD symptoms, and has consistently for the past 6 months used a therapeutic dose of a PPI.  He states he is “really no better with the medicine.” He further states he has avoided most of the food that bothers his stomach and all alcohol and soda. The physical examination reveals weight loss, mildly erythematous pharynx with mild dysphagia, and epigastric tenderness without rebound.  You would consider at this time:

The PTC’s decision-making process must align with SORT and AGREE II principles by:

Which scenario illustrates effective linkage of STG-based EML selection and procurement?

If quantification blends consumption data with anticipated STG changes and disease prevalence shifts, the outcome is:

ScenarioIn a large public hospital network in Gauteng, the Provincial Pharmacy & Therapeutics Committee (PTC) faces complex challenges. First, clinicians request inclusion of a new oncology biologic “Oncimab” for metastatic cancer cases—not on the national EML/STG. They provide observational data suggesting modest survival gain and cite a single phase III trial with SORT grade B evidence. The provincial procurement office advises that adding Oncimab could raise the Medicine drug budget by 12 %, risking stockouts of essential antiretrovirals due to limited tenders. Simultaneously, routine Medication Use Evaluation (MUE) audits show that third generation cephalosporins are being over prescribed in surgical prophylaxis, deviating from STGs and generating resistance concerns. Inventory data from the supply depot reveal inconsistent stock reporting and frequent depletion of first line ARVs, despite quantification based on historical consumption. The procurement committee must consider preferential procurement rules favouring local generic suppliers when quality/effectiveness is comparable. External intelligence indicates that manufacturer supplied pharmacoeconomic models for Oncimab may be biased. The PTC must weigh clinician motivation, evidence quality, budget impact, rational use audits, STG adherence, and compliant quantification and procurement practices—including preferential policy—for rational and equitable access decisions.

Which two elements must PTC integrate when considering Oncimab inclusion?